Table 2.

Impact of Anticancer Treatments on COVID-19 Severity

Summary of Select Studies Exploring the Impact of Cancer Treatments on COVID-19 Severity
Study	Country/Countries	Cancer Types	Number of Patients With COVID-19	Key Insights
Grivas et al.42	95% in U.S.	All cancer	4966	Recent (past 3 mo) cytotoxic chemotherapy associated with severe COVID-19 (OR = 1.28) and 30-d mortality (OR = 1.61). Noncytotoxic anticancer therapies, including immunotherapy, targeted therapy, and endocrine therapy not associated with severe COVID-19 nor 30-d mortality
		Thoracic	409
Kuderer et al.47	U.S.	All cancer	928	No association between 30-d all-cause mortality and recent surgery, recent noncytotoxic therapy, or recent cytotoxic systemic therapy
		Thoracic	91
Pinato et al.45	UK, Italy, Spain, and Germany	All cancer	890	No association between cytotoxic chemotherapy, targeted therapy, or immunotherapy and COVID-19 severity
Lee et al.44	UK	All cancer	800	No significant mortality effect for recent (past 4 wk) chemotherapy, immunotherapy, hormonal therapy, targeted therapy, or radiotherapy
		Respiratory and intrathoracic organs	90
Mehta et al.78	U.S.	All cancer	218	Neither chemotherapy nor radiotherapy associated with
		Lung	11	increased case fatality rate
Garassino et al.7	Mostly Italy, Spain, and France	Thoracic cancer	200	In multivariable analysis, TKIs, chemotherapy, and immunotherapy, not associated with increased mortality
Luo et al.41	U.S.	Lung cancer	102	No observed impact of TKIs or chemotherapy and COVID-19 severity
Luo et al.6	U.S.	Lung cancer	69	No significant association between PD-1 blockade and COVID-19 severity

Note: Active cancer treatments do not worsen COVID-19 outcomes in patients with cancer and COVID-19.

COVID-19, coronavirus disease 2019; PD-1, programmed cell death protein-1; TKI, tyrosine kinase inhibitor; U.S., United States; UK, United Kingdom.